PURPOSE: To correlate the structural and functional changes following intravitreal injection of @entity619 0.7 mg (Ozurdex  ) implant in @entity1 with recalcitrant uveitic @entity1103 ( @entity1103 ). MATERIALS AND METHODS: In a prospective, interventional, nonrandomized study, 30 eyes (27 @entity1 ) with uveitic @entity1103 received Ozurdex   implant and were followed-up for 24 weeks at periodic intervals to monitor structural alterations seen on spectral domain optical coherence tomography (SD-OCT). The outcome measures included change in @entity1020 ( @entity1020 ) and best-corrected visual acuity (BCVA) as well as structural alterations seen on OCT such as change in the height of cystoid spaces (CSs) and @entity1713 ( @entity1713 ). The integrity of external limiting membrane and inner-outer segment junction was assessed at baseline and follow-up visits. RESULTS: Mean age of the @entity1 was 46.09    15.66 years. The mean @entity1020 decreased by 96  m at 1-day, 231.64  m at 1-week, 254.21  m at 4 weeks and 249.14  m at 12 weeks (P < 0.001) compared with baseline. BCVA improved from a baseline mean of 0.62 LogMAR units to 0.49 on day 1 to 0.31 at 24 weeks (P < 0.001). A decrease in the mean height of @entity1050 , that is, 133.28  m from a baseline of 317.71  m was noted on the 1 st day (P < 0.001). 4 eyes demonstrated the presence of @entity1050 at 4 weeks, 1 eye at 6 weeks and 3 eyes at 12 weeks. At baseline, 16 eyes (53.33%) demonstrated the presence of @entity1713 . Among these, 11 eyes showed resolution of @entity1713 on day 1. @entity1713 resolved in all @entity1 at 4 weeks and was maintained up to 24 weeks. CONCLUSIONS: Ozurdex   implant improves the visual outcome of @entity1 with recalcitrant uveitic @entity1103 . Reversibility of retinal changes may be possible following treatment with @entity619 implant. Thus final visual outcome may be independent of pretreatment @entity1020 , the height of @entity1050 or @entity1713 .

Spectral domain optical coherence tomography changes following intravitreal @entity619 implant, Ozurdex   in @entity1 with uveitic XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1713 :: ('MESH:D012163', 'Disease') :: ['SSRD', 'sub-foveal serous retinal detachment'] @entity1050 :: ('MESH:D006223', 'Disease') :: ['CS'] @entity1103 :: ('MESH:D008269', 'Disease') :: ['CME', 'cystoid macular edema'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['CMT', 'central macular thickness']
@entity1103 :: (MESH:D008269,Disease) :: ['cystoid macular edema']
